OM1, in order to outspread its activities on product development, marketing or sales, has hiked for its financing needs, around $50 million. This analytics company helps hospitals as well as pharma companies to get clinical insights. These insights provided by this big-data analytics company are used to improvise on various treatments. These are further helpful in the utilization of certain drugs in the most efficient manner.
On this act, the founder and CEO of OM1, Dr. Richard Gliklich stated, “Clinical outcomes are the most important metric in healthcare. With this funding, OM1 will accelerate our work towards delivering rapid access to real-world outcomes and evidence. Also, it will help our customers apply those data in impactful ways.”
This move by OM1 further involved 7wire Ventures, existing investors, Polaris Partners, General Catalyst (GC), Scale Venture Partners, and more. Moreover, acquiring a place in the board of directors of the company, in his statement, O’Driscoll stated, “AI and data are driving factors in the transformation of many industries.”
“OM1 is at the forefront of bridging these two in transformative ways in healthcare and we are excited to be part of the journey to drive the better development of medicine and delivery of care,” O’Driscoll, Scale Venture Partners’ managing director, further stated
This company, however, was founded by Dr. Gliklich in 2015. Moreover, the company’s main area of interest involves chronic conditions such as rheumatology, central nervous system, immunology, and musculoskeletal conditions. It further includes the treatment of cardiometabolic disorders and behavioral health technologies.